mRNA Pharmaceuticals

mRNA technology for next generation treatments

BioNTech is building platforms in 3 therapeutic areas using a variety of mRNA technologies to create pharmacologically optimized protein coding RNAs for targeted in vivo delivery

  • Cancer immunotherapies
  • Infectious disease vaccines
  • Protein replacement

Cancer Immunotherapies

Creating individualized therapies to transform cancer treatment

Every tumor has an exclusive pattern of tumor antigens which is based on acquired mutations. Even within the same type of cancer, only a small percentage of mutations is shared, most of them are absolutely unique for each and every patient. At BioNTech, we use next-generation sequencing (NGS) and proprietary analytical algorithms to define these tumor-specific antigen signatures. Using these signatures or “mutanomes” we generate treatments tailored to target each individual tumor. We have developed an mRNA-based cancer immunotherapy platform that utilizes the tumor-specific information to develop personalized treatments for each patient. The goal is to activate each patient’s immune system to recognize, target and fight their individual cancer. To achieve this goal, we have developed several different versions of our individualized cancer vaccines that become progressively more personalized including the FixVAC®, RNA WAREHOUSE® and iNeST® programs.


Our Vision is…
… to use WAREHOUSE and iNeST® vaccines to make multiple cancers treatable and improve the survival of patients suffering from the most aggressive tumors.
… to make the WAREHOUSE and iNeST® platforms a standard tool for personalized RNA-based cancer therapy.

Prophylactic Vaccines

Potent prophylactic vaccines to stop epidemic threats

Previous epidemics have taught us that emerging viruses can quickly cause a global crisis. Conventional vaccines are usually based on inactivated or engineered viruses that often require seasonal and accurate selection of specific viral strains and cannot be produced fast enough to stop a rapidly spreading pandemic. As globalization reaches remote locations, new vaccine approaches are urgently needed to respond quickly to new epidemic threats. To meet this challenge, we are developing an innovative self-amplifying RNA-based Ribological RNA Amplicon Vaccine Platform against infectious diseases (A.I.R®; Amplified Immune Response) that has the potential to deliver millions of doses of prophylactic vaccines for a given viral threat within the shortest time possible.

Our Vision is…
.. to use A.I.R.® for the development of infectious disease vaccines.
… to make A.I.R.® a standard tool for rapid response vaccine strategies against viral threats.

Click here for more information.

BioNTech is part of the EAVI2020 consortium for the development of an effective HIV vaccine. BioNTech will develop novel, highly immunogenic, prophylactic and therapeutic vaccine candidates based on our A.I.R. technology platform. For more information visit the EAVI2020 Website.

Protein Replacement

World class science in protein replacement

BioNTech’s mRNA protein replacement program is led by Prof. Katalin Karikó, a world-renowned expert in the field of mRNA biochemistry. The program is mainly focused on rare genetic diseases and uses BioNTech’s non-immunogenic mRNA platform and proprietary technologies for delivery of mRNA encoding therapeutic proteins or antibodies into the human body.

Other opportunities for the program include novel solutions for expression of therapeutic antibodies using intra-muscular mRNA delivery and expression of immunomodulatory proteins.